Genialis’ Post

97% of clinical trials for cancer therapies fail — but perhaps AI could help. The industry is turning to AI to find novel biomarkers which could reveal the underlying causes of vastly different treatment responses across patient populations. 🧬 Genialis and Nucleai, two startup investments from Debiopharm Innovation Fund promise to transform oncology drug development, as part of the fund’s wider AI-focused portfolio. We spoke to the startups — and their investors — to find out what they are working on. 👉 https://lnkd.in/g62APAKh #Ad with Debiopharm  #biotech #healthtech #deeptech #cancertech Featuring insights from Carolina Haefliger, head of translational medicine at Debiopharm, Rafael Rosengarten, CEO and cofounder of Genialis, Marc Cikes, managing director of Debiopharm Innovation Fund, Avi Veidman, CEO and cofounder of Nucleai and Anna Pokorska-Bocci, principal scientist in personalised medicine at Debiopharm.

I am excited to announce, that ZAKA VC has invested in another ground-breaking project in the forefront of biotech. Eigen Therapeutics leads the way in redefining the precision cancer treatment. Since no two cancers are the same, there’s a need to combine therapies which are very effective. The problem is that you’re usually looking at various targets at once – so knowing which are the right ones and aiming at them precisely is the key. The more accurate your “aim” is the lesser chance is there for cancer cells to escape the treatment. This helps not only in improving outcomes for patients but also reducing the side effects of the treatment. The Eigen Therapeutics’ team, under a leadership of CEO and Co-Founder Transon Nguyen, CTO and Co-Founder Kamran A., and Chief Scientific Officer Kathryn Vanderlaag, is combining multidisciplinary knowledge and building a platform to scale co-therapy development. They’re using machine learning and automation to improve existing targeted therapies, develop new combination therapies, and make them available for a wider range of cancers. Alongside ExcepGen, Sensible Biotechnologies, and Olio Labs, Eigen Therapeutics is another great addition to ZAKA VC portfolio. The partnership with a company that already collaborates with top Silicon Valley funds continues to strengthen our commitment to advancements in the biotech sector. #newinvestment #biotech #precisionmedicine #eigentherapeutics

Delphia Therapeutics just launched with a $67M boost, ready to revolutionize oncology through 'activation lethality.' It's about turning cancer's strength into its downfall by over activating cell pathways until they can't cope. 💡🔬 I'm intrigued by the groundbreaking approaches shaping the MedTech field. Delphia's debut could be a game-changer for organizations and talent in the HealthTech ecosystem. Let's watch this space for their journey to clinical trials! 💊🧬 #CancerResearch #Innovation #HealthTech

I truly enjoyed my on-site visit to our EIC Accelerator beneficiary Celeris Therapeutics in Graz, Austria. Celeris Therapeutics develops much-needed medicine against currently incurable diseases, focusing on cancers. Utilizing advanced artificial intelligence (AI) combined with wet lab automation, the company aims to unravel the complexities of cancer at a cellular level. This innovative approach allows us to target pathogenic proteins precisely, removing the cause of the disease by exploiting natural cell-based mechanisms with swallowable pills. Christopher Trummer, CEO and Co-Founder of Celeris Therapeutics mentioned: “By focusing on the intricate mechanisms of cancer, we're working to offer more effective treatment options that could potentially transform the landscape of cancer care. Our mission is to bring new hope to patients, and we're committed to making that a reality." He continued: "Our European funding via EIC Accelerator enabled us to develop our in-house lab, which allows testing of the AI algorithms at our own facilities.” To know more about EIC Accelerator funding opportunities, check out EIC 2024 Work Programme https://europa.eu/!VDTvQ7 European Innovation Council and SMEs Executive Agency (EISMEA) #EUeic, #eicAccelerator, #AI, #MedTech

Did you know that Certis is the only translational partner that combines the predictive power of artificial intelligence with advanced models of cancer to evaluate efficacy and understand the complex mechanisms of action inherent to drugs that target RAS pathways? Join us at the Hanson Wade Group RAS-Targeted Drug Development Summit in Boston, MA on September 26-28 to learn more about our unique KRAS-mutant cancer models and how we can help you validate your KRAS-targeting drug development strategy. Stop by our exhibit booth or book a meeting with Chief Business Development Officer Debbie Snyder-Stanton, MBA, if you prefer: https://hubs.la/Q022hSCC0. #RAS #DrugDevelopment #CancerResearch #HitYourTarget #KRAS #OncogenicDrivers #CertaintyisPriceless #AI #artificialintelligence

Prepare to be inspired! Speaker Spotlight: Dr. Jagath Reddy Junutula We are ecstatic to announce that Dr. Jagath Reddy Junutula, a titan in oncology drug discovery and development, will be sharing his wealth of knowledge at our Drug Discovery & Development Workshop! With an illustrious career exceeding three decades, Dr. Junutula has been at the forefront of innovation, notably contributing to significant breakthroughs in cancer therapy. His pioneering efforts in THIOMAB technology have significantly advanced the field of antibody-drug conjugates, paving the way for groundbreaking advancements in cancer therapy. At our workshop, Dr. Junutula will dive deep into the essentials of drug discovery, shedding light on target identification & validation, and the crucial role of small molecules. Furthermore, he's set to provide an in-depth exploration of the promising domain of designer drugs — a session you surely wouldn't want to miss. This is your chance to absorb knowledge from a visionary in the field! Register now to attend Dr. Junutula's sessions and unlock insights that could redefine your perspective on drug discovery and development. Make sure to secure your place and elevate your expertise in the evolving landscape of biotechnology! Don't miss out! Register here: https://lnkd.in/ekGgYQkZ #DrugDiscovery #PrecisionMedicine #FABAInnovationSummit2024 #Biotech #PharmaIndustry

Kurt Gish, Ph.D., Joins BioLoomics As Chief Scientific Officer Learn more & get our take 👇 https://lnkd.in/gEXwhJ7N “Kurt is an impressive and accomplished scientist that sits at the intersection of ADCs, peptides, and target discovery/validation. He has a deep understanding of how improper spatial targeting of ADCs has limited the field. With his deep experience in the ADC space, I am confident that Kurt will be invaluable to advancing BioLoomics’s technology to build safer and more efficacious ADCs for both strategic partners and internal programs.” — Dr. Doug Chapnick, CEO and Founder at BioLoomics “BioLoomics is developing incredible technology to deliver more therapeutic drug directly into cancer cells while minimizing systemic toxicity. I’m thrilled to join such an innovative team and look forward to getting the best possible treatments to patients that so desperately need them.” — Dr. Kurt Gish, Chief Scientific Officer at BioLoomics #leadership #bio #SoHCNews

⚡️Great article in Sifted about Avonmore Developments portfolio company Concr ⚡️Concr is using techniques derived from astrophysics to pull together disparate and sparce data sources to provide more effective and targeted oncology therapies

Meet IntraGel Therapeutics, an Asper Prize 2024 Finalist! What is their #StartupStory? Intragel, founded in 2021 by CEO Peter Siman after his mother’s death from untreatable lung cancer, addresses the needs of 8 million inoperable cancer patients. About 40% of these patients, like Peter’s mother, cannot undergo chemotherapy due to toxicity concerns. Intragel’s innovation, SRGel, is a patent-protected gel-like polymer capable of incorporating up to 50% drug payload. Applied directly into tumors, SRGel releases the drug over several weeks, replacing multiple chemotherapy courses, enhancing intratumoral drug concentration and efficacy with minimal systemic toxicity, hitting the jackpot of interventional oncology space. This breakthrough technology showed promise in Phase 1 clinical trials for chemo- and radio-resistant Head and Neck cancer.  Intragel is currently raising $10 million to finalize Phase I trials, build a GMP production facility, execute Phase II trials, and fund marketing efforts. Follow along to see if they will be the rising Startup of the year! The Hebrew University of Jerusalem, Asper Foundation, Yissum, The Hebrew University Tech Transfer Company, Amnon Dekel, PhD, Peter Siman Bridges Israel, Deep Insight, Grove Ventures, JVP, Meron Capital, OurCrowd, PICO Venture Partners , Target Global, 10D #technology #startup #innovation #asperprize 

Provectus Therapeutics has developed a cost-effective, advanced culture plate designed for single cell culture and analysis. This platform is ideal for studying tumor heterogeneity, phenotypic plasticity, and off-target mechanisms in oncology. Visit the post below for more details! #AI #cancer #drugdevelopment #precisionmedicine